4 years ago

Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database

To assess the impact of adjuvant treatment, sociodemographic and tumor factors on the survival of patients with non-metastatic clear cell endometrial carcinoma (CCC). Methods 4298 patients treated from 1998 to 2011 with Stage I–IVA CCC were identified within the National Cancer Database. FIGO 2009 staging system was used. Adjuvant groups included: hysterectomy (HYS); HYS+vaginal brachytherapy (VBT); HYS+chemotherapy (CT); HYS+external beam radiation therapy (EBRT); HYS+CT+EBRT; and HYS+CT+VBT. Univariable (UVA) and multivariable (MVA) frailty survival analyses were performed. Results On UVA, higher stage was associated with an increased risk of death. Compared to stage I–IA, the risk of death for stage IB was HR 1.75 (95% CI, 1.50–2.04; p <0.001), stage II was HR 1.77 (95% CI, 1.50–2.10; p <0.001), stage III–IIIB was HR 3.29 (95% CI, 2.86–3.80; p <0.001), stage IIIC–IIIC2 was HR 3.33 (95% CI: 2.94–3.77; p <0.001), and stage IVA was 8.59 (95% CI: 6.60–11.18; p <0.001). Other meaningful predictors of death included black race (p <0.001), public insurance (p <0.001), geographic education attainment (p =0.001), greater comorbidity score (p =0.001), increasing age (p <0.001), and increasing tumor size (p <0.001). After controlling for stage, insurance, race, education attainment, comorbidity score, age, and tumor size adjuvant treatment was not associated with decreased risk of mortality (p =0.26). Conclusion Adjuvant therapy did not have a meaningful effect on survival in this sample from the National Cancer Center Database. Given the aggressive nature of the disease, clinical trials are required to determine the optimal adjuvant therapy in patients with non-metastatic CCC to improve clinical outcomes.

Publisher URL: www.sciencedirect.com/science

DOI: S0090825817315068

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.